Posted On: 06/12/2014 11:36:04 PM
Post# of 30066
MJFF & AMBS
All eyes on AMBS, new and old, should read the latest Investor Presentation from the AMBS website. This was updated April 7, 2014. Could stir up some good questions for the shareholder update.
This is one of the many highlights.
MJFF on the Eltoprazine Data
“Dyskinesia is a top priority for the Foundation because of its impact on the quality of life of people living with Parkinson’s disease,”
“The results show early promise in finding a potential treatment for dyskinesia, and we look forward to working with this team to drive their program forward .”
Todd Sherer, PhD, CEO of The Michael J. Fox Foundation .
http://content.stockpr.com/amarantus/media/3b...121792.pdf
All eyes on AMBS, new and old, should read the latest Investor Presentation from the AMBS website. This was updated April 7, 2014. Could stir up some good questions for the shareholder update.
This is one of the many highlights.
MJFF on the Eltoprazine Data
“Dyskinesia is a top priority for the Foundation because of its impact on the quality of life of people living with Parkinson’s disease,”
“The results show early promise in finding a potential treatment for dyskinesia, and we look forward to working with this team to drive their program forward .”
Todd Sherer, PhD, CEO of The Michael J. Fox Foundation .
http://content.stockpr.com/amarantus/media/3b...121792.pdf
(0)
(0)
